Cas 708274-37-7,8-(5-bromopyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ol

708274-37-7

Post Buying Request

Basic information

Product Name: 8-(5-bromopyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ol
Synonyms: 8-(5-bromopyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ol;8-(5-Bromo-2-pyridyl)-8-hydroxy-1,4-dioxaspiro[4.5]decane;EOS-61903
CAS NO:708274-37-7
Molecular Formula: C₁₃H₁₆BrNO₃
Molecular Weight: 314.17504
EINECS: N/A
Product Categories: N/A
Mol File: 708274-37-7.mol

Chemical Properties

Melting Point: N/A
Boiling Point: 434.6±45.0 °C(Predicted)
Flash Point: N/A
Appearance: /
Density: 1.56±0.1 g/cm3(Predicted)
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
PKA: 13.03±0.20(Predicted)
CAS DataBase Reference: 8-(5-bromopyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ol(CAS DataBase Reference)
NIST Chemistry Reference: 8-(5-bromopyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ol(708274-37-7)
EPA Substance Registry System: 8-(5-bromopyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ol(708274-37-7)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 708274-37-7(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

708274-37-7 Suppliers

Recommended suppliers

708274-37-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 708274-37-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,0,8,2,7 and 4 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 708274-37:
(8*7)+(7*0)+(6*8)+(5*2)+(4*7)+(3*4)+(2*3)+(1*7)=167
167 % 10 = 7
So 708274-37-7 is a valid CAS Registry Number.

708274-37-7Upstream product

708274-37-7Downstream Products

708274-37-7Relevant academic research and scientific papers

Discovery of INCB8761/PF-4136309, a potent, selective, and orally bioavailable CCR2 antagonist

Xue, Chu-Biao,Wang, Anlai,Han, Qi,Zhang, Yingxin,Cao, Ganfeng,Feng, Hao,Huang, Taisheng,Zheng, Changsheng,Xia, Michael,Zhang, Ke,Kong, Lingquan,Glenn, Joseph,Anand, Rajan,Meloni, David,Robinson,Shao, Lixin,Storace, Lou,Li, Mei,Hughes, Robert O.,Devraj, Rajesh,Morton, Philip A.,Rogier, D. Joseph,Covington, Maryanne,Scherle, Peggy,Diamond, Sharon,Emm, Tom,Yeleswaram, Swamy,Contel, Nancy,Vaddi, Kris,Newton, Robert,Hollis, Greg,Metcalf, Brian

, p. 913 - 918 (2011)

We report the discovery of a new (S)-3-aminopyrrolidine series of CCR2 antagonists. Structure-activity relationship studies on this new series led to the identification of 17 (INCB8761/PF-4136309) that exhibited potent CCR2 antagonistic activity, high sel

A METHOD OF TREATING LIVER FIBROSIS

-

Page/Page column 59, (2012/09/11)

The present invention relates to a method of treating hepatis C and/or liver fibroisis with 3-cycloalkylaminopyrrolidine derivatives of the present invention

4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2

-

Page/Page column 36, (2010/06/19)

The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, and R4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).

3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors

-

Page/Page column 32, (2008/06/13)

The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 708274-37-7